Prosecution Insights
Last updated: October 02, 2026

Examiner: SAEED, KAMAL A

Tech Center 1600 • Art Units: 1623 1626

This examiner grants 84% of resolved cases

Analysis

Kamal A Saeed is an examiner in Tech Center 1600 and Art Unit 1623. The examiner has 1212 resolved cases. The allowance rate for these matters is 83.8%. This metric provides a baseline for the likelihood of securing a patent grant during prosecution. The 83.8% rate is a primary data point for evaluating the probability of success in this specific Art Unit.

The interview lift is 9.8%. This value measures the increase in the probability of allowance following an interview. A lift of 9.8% indicates that engaging in a direct dialogue with the examiner can be a factor in the progression of cases. Practitioners should weigh this 9.8% figure when deciding whether to request a formal interview for their 1212 resolved cases.

The median days to allowance is 759. This figure represents the typical time span from filing to the issuance of a patent. A median of 759 days informs the scheduling and budget expectations for applicants. This 759 days duration is a factor in the overall prosecution timeline.

In Tech Center 1600, the examiner's 83.8% allowance rate and 1212 resolved cases define the current landscape. The interview lift serves as a tool for navigating the prosecution process toward a grant.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

83.9%
Allow Rate
+23.9% vs TC avg
1,227
Total Applications
+9.8%
Interview Lift
759
Avg Prosecution Days
Based on 1214 resolved cases, 2023–2026

Rejection Statute Breakdown

2.5%
§101 Eligibility
6.9%
§102 Novelty
9.0%
§103 Obviousness
16.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17913292 Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor Inhibitors Final Rejection Novo Nordisk A/S
18847898 A METHOD OF PRODUCING EXPLOSIVE HMX BY FLOW SYNETHESIS Non-Final OA BAE SYSTEMS PLC
18210215 BLEND CONTAINING CARBAMATE COMPOUND FOR PREVENTION, MITIGATION, OR TREATMENT OF SCHIZOPHRENIA Final Rejection SK BIOPHARMACEUTICALS CO., LTD.
18872318 HSD17B13 INHIBITORS Non-Final OA Boehringer Ingelheim International GmbH
18500142 METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS AND METHOD FOR SUPPRESSING PROGRESS OF AMYOTROPHIC LATERAL SCLEROSIS Final Rejection Shionogi Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month